News

Parkinson's Disease Drug Market Forecasted To Cross Valuation Of $10.4 Billion By 2031
The global Parkinson's disease drugs market size is projected to reach $10.4 billion by 2031, growing at a CAGR of 6.2% from 2022 to 2031.
Ocugen: Three Potential Gene-Therapy Filings By 2028
Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...
Deccan Chronicle1d
Incretin Therapy: Bane Or Boon To Weight Loss
Among a plethora of weight-management plans and dietary charts (namely, keto, dash, sirtfood, paleo or crash diet), climbing ...
DutchPilotGirl on MSN1d
Aviation adventure: crosswind challenges
Join me as I take you on a journey to Milan Malpensa, Italy, showcasing a gusty crosswind landing in a Boeing 737-400 (Boeing ...
Kalkine Media1d
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
Outlook Therapeutics, Inc. (Nasdaq:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will ...
Two major US food producers to remove artificial dyes from products sold domestically
Real-time index price for S&P 500 Industrials [Sector] (SRIN), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
NDTV Profit on MSN1d
Stock Market Live: Nifty, Sensex Erases Loss As RIL, M&M Shares Lead
The Securities and Exchange Board of India granted the National Stock Exchange Tuesday as its stock derivatives expiry day, ...
thederrick.com2d
FDA to offer faster drug reviews to companies promoting 'national priorities'
The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...